The B 1 receptor for kinins is selectively stimulated by bradykinin-related fragments lacking the C-terminal arginine, des-arginine 9 -bradykinin (des-Arg 9 -BK), and Lys-des-Arg 9 -BK. The latter peptide is the optimal agonist at the human and rabbit receptor. The B 1 receptor is inducible as a function of inflammatory conditions in the vasculature. We studied the effect of endogenously expressed peptidases on the potency of ligands of this receptor in an established bioassay, the rabbit aorta contractility. The potency measured for agonists (EC 50 ) or antagonists (pA 2 scale) in this assay was compared with the affinity of each agent determined using 
peptidase N mediates most of the distortion (inhibited by amastatin but not efficiently by puromycin). At the other end of the spectrum, the fully protected agonist Sar-[D-Phe 8 ]des-Arg 9 -BK is not significantly potentiated by peptidase inhibitors. A similar distortion of apparent potency was observed for some peptide antagonists used in the contractility assay, B-10350 (Lys-Lys- [Hyp 3 , Igl 5 , D-Tic 7 , CpG 8 ]des-Arg 9 -BK) and Lys- [Leu 8 ]des-Arg 9 -BK being intensely potentiated by amastatin treatment and effective L-Ala-p-nitroanilide competitors. N-Protected peptide antagonists or a nonpeptide antagonist of the B 1 receptor were not potentiated by amastatin. The coexpression of aminopeptidase N and the kinin B 1 receptor in rabbit arterial tissue is of interest for the inactivation of the high-affinity agonist Lys-des-Arg 9 -BK and for the design of hydrosoluble antagonist drugs.
Bradykinin-related peptides, the kinins, stimulate cellular functions following binding to two types of receptors predominantly coupled to the G q protein, the B 1 and B 2 receptors (Leeb-Lundberg et al., 2005) . In the vasculature, the B 1 receptor is essentially an inducible gene product in most mammalian species (Marceau et al., 1998) . Kinins exert antiproliferative effects on injured or cultured vascular smooth muscle cells via the B 1 receptors, and its expression has been shown in human atheromas (Raidoo et al., 1997; Agata et al., 2000; Dixon et al., 2002) . Ischemia induces endothelial B 1 receptor expression, and there is mounting evidence, partly based on B 1 receptor gene knockout mice, that the B 1 receptor may play a detrimental role opposed to that of the B 2 receptors in ischemia-reperfusion systems (Mazenot et al., 2001; Lagneux et al., 2002; Souza et al., 2004) . B 1 receptor mediation of ischemia-driven angiogenesis has been shown (Emanueli et al., 2002) . Of relevance to sepsis, vascular B 1 receptor expression-mediating hypotension also occurs following sublethal lipopolysaccharide treatments in various species (McLean et al., 1999; Schanstra et al., 2000; deBlois and Horlick, 2001; Leeb-Lundberg et al., 2005) . Whether inducible B 1 receptors mediate a part of the therapeutic or This work was supported by the Canadian Institutes of Health Research Grant MOP-14077 and the Fonds de la Recherche en Santé du Québec (studentship award to J.-P.F.).
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B 1 receptors are stimulated by specific sequences derived from kininogens, namely des-arginine 9 -bradykinin (desArg 9 -BK) and Lys-des-Arg 9 -BK (des-Arg 10 -kallidin), that are metabolites of native kinins (bradykinin and lysyl-bradykinin or kallidin) via the action of arginine carboxypeptidases (Leeb-Lundberg et al., 2005) . These peptides, like all the kinins, are short-lived in vivo. Among the peptidases that hydrolyze kinins, porcine endothelial and smooth muscle cells express an aminopeptidase activity inhibited by amastatin (more by the latter cell type; Palmieri et al., 1989) . This enzyme reportedly hydrolyzes lysyl-bradykinin (kallidin) and Lys-des-Arg 9 -BK but not bradykinin or des-Arg 9 -BK (Palmieri et al., 1989; Drapeau et al., 1991a) . The N-terminal Lys residue is a major determinant of affinity for the human, porcine, and rabbit B 1 receptors (Leeb-Lundberg et al., 2005) , and the optimal agonist of these receptors, Lys-des-Arg 9 -BK, produced a prolonged hypotensive response in amastatintreated, lipopolysaccharide-pretreated rabbits (Drapeau et al., 1991b) , supporting the idea that cardiovascular responses produced by this agonist and mediated by B 1 receptors in vivo are arrested by an aminopeptidase.
The importance of peptidases in the inactivation of B 1 receptor ligands has also been shown by structural modifications. Sar-[D-Phe 8 ]des-Arg 9 -BK has a decreased affinity relative to Lys-des-Arg 9 -BK at the rabbit and human B 1 receptor based on radioligand binding assays (Sabourin et al., 2002a; Leeb-Lundberg et al., 2005) , but it gained resistance to several peptidases present in blood plasma and kidney membranes (Drapeau et al., 1993) and is a highly persistent hypotensive agent in lipopolysaccharide-pretreated rabbits (Drapeau et al., 1991b; Audet et al., 1997) . The prototype antagonist of the B 1 receptors, Lys- [Leu 8 ]des-Arg 9 -BK, has also been subjected to such structural analysis (Drapeau et al., 1993) . The introduction of synthetic amino acid residues that constrain the peptide backbone has had a major impact in this field, with the production of antagonists that retain high potency (e.g., B-9958; Larrivée et al., 2000) . Inflammatory pain has been their most investigated application (LeebLundberg et al., 2005) .
The present study aims at evaluating the relative importance of the endogenous peptidases in the inactivation of peptide ligands of the rabbit B 1 receptor using the contractility of the rabbit aorta. Peptidase-mediated distortions in apparent potency of the B 1 receptor peptide agonists and antagonists have been pharmacologically addressed. A novel nonpeptide antagonist (Ransom et al., 2004 ) was compared with peptide antagonists in this respect. An enzymatic approach was also used to measure the susceptibility of peptide ligands to an endogenously expressed aminopeptidase N (also called aminopeptidase M, CD13, and EC 3.4.11.2). The latter enzyme emerges as the major inactivation pathway for both peptide agonist and antagonists of the B 1 receptors at the vascular level.
Materials and Methods
Drugs. Compound A and compound 11 are selective nonpeptide hydrophobic B 1 receptor antagonists (Morissette et al., 2004; Ransom et al., 2004) . Ac-Lys [Leu 8 ]des-Arg 9 -BK is a documented B 1 receptor antagonist (Drapeau et al., 1993) , and B-10350 is a close analog of B-9958 (Larrivée et al., 2000) (Drapeau et al., 1991a (Drapeau et al., , 1991b (Drapeau et al., , 1993 . The other drugs were from Sigma-Aldrich (St. Louis, MO). The sequences of the peptide ligands are aligned in Table 1 .
Contractility Studies. A local ethics committee approved the procedures based on rabbits. Rabbit aortic rings with intact endothelium (New Zealand White, 1.5-2 kg; Charles River Canada, Montreal, QC, Canada) were suspended under a tension of 2 g in 5-ml tissue baths containing oxygenated (95% O 2 /5% CO 2 ) and warmed (37°C) Krebs' solution as previously described (Morissette et al., 2004) . Contractility studies were performed after 3 or 5.5 h of in vitro incubation because the response mediated by B 1 receptors is acquired in a time-and protein synthesis-dependent manner in this preparation (Leeb-Lundberg et al., 2005) . In experiments dealing with antagonists, the procedure described by Morissette et al. (2004) was precisely applied (construction of cumulative concentration-response curves for des-Arg 9 -BK at times 3.5 and 5.5 h from the beginning of the incubation of the preparation; antagonists or their vehicle were introduced 30 min before the construction of the second curve; pA 2 value calculation as described). The curves constructed at 3.5 h are internal controls, and only the second ones are shown. In experiments dealing with agonists, cumulative concentration-effect curves (5.5 h) were determined for des-Arg 9 -BK, Lys-des-Arg 9 -BK, or Sar-[D-Phe 8 ]des-Arg 9 -BK in separate tissues for the determination of apparent contractile potencies. Additional concentration-effect determinations were performed in the presence of a mixture of pepti- Ac, N-acetyl; CpG, ␣-cyclopentylglycine; Hyp, trans-4-hydroxyproline; Igl, ␣-(2-indanyl)glycine; Sar, sarcosine (N-methylglycine); Tic, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid. dase inhibitors (3 M amastatin, 1 M captopril, and 1 M phosphoramidon) or of separate peptidase inhibitors introduced 45 min before the construction of the second concentration-effect curve. These concentrations of peptidase inhibitors are similar to those used in metabolic studies dealing with the metabolism of bradykininrelated peptides (Palmieri et al., 1985; Orawski et al., 1989; Drapeau et al., 1993) . Contractility results were expressed as a percentage of the maximal response recorded in each tissue (all the antagonists used were surmountable as judged by the conservation of the E max from the first concentration-effect curve).
Binding Assay. The binding of 1 nM [ 3 H]Lys-des-Arg 9 -BK (80 Ci/mmol) (PerkinElmer Life and Analytical Sciences, Boston, MA) to adherent intact rabbit aortic smooth muscle cells was evaluated as described in cells maintained in the culture medium supplemented with 10% fetal bovine serum and interleukin-1␤ (5 ng/ml for the last 4 h) (Sabourin et al., 2002b) . The assay was applied to evaluate binding competition by unlabeled drugs. These drugs were present during the 60-min period allowed for radioligand binding equilibration in the binding buffer (consisting of Medium 199 supplemented with 0.1% bovine serum albumin, 3 M amastatin, 1 M captopril, 1 M phosphoramidon, and 0.02% sodium azide w/v). K i values for unlabeled competitors were derived from the relationship
, where K D is the dissociation constant of the radioligand, S is the radioligand concentration, and IC 50 is the unlabeled drug concentration that displaces half of the specific radioligand binding (graphic determination).
Membrane and Cytosol Preparations: Enzymatic Assay. Several primary lines of rabbit aortic smooth muscle cells were initiated and cultured as previously described (Sabourin et al., 2002b) . Bovine aortic endothelial cells (BAECs; gift from Dr. Darren Richard, Centre Hospitalier Universitaire de Québec, Quebec City, QC, Canada), maintained in Dulbecco's minimum essential medium supplemented with 10% fetal bovine serum, were selected for their low background expression of membrane aminopeptidase activity. They were transfected as previously described (Sabourin et al., 2002a) with the vector coding for human aminopeptidase N fused to green fluorescent protein (APN-GFP), a variant based on the BD Biosciences Clontech (Palo Alto, CA) pEGFP-N1 vector of a reported fluorescent fusion protein (Kehlen et al., 2003 ; gift from Dr. Astrid Kehlen, Institute of Medical Immunology, University of Halle-Wittenberg, Halle, Germany). Membranes from either cell type or from freshly de-endothelialized rabbit aortic rings (representing smooth muscle) or a cytosolic fraction from smooth muscle cells were prepared as sources of enzyme. Briefly, cells or tissues were homogenized (up to 24, 75-cm 2 flasks per day or ϳ50 mg of fresh tissue) in 0.5 ml of sucrose buffer [250 mM sucrose, 20 mM N-[2-hydroxy-1,1-bis(hydroxymethyl) ethyl]glycine buffer, 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml leupeptin, 2 mg/ml pepstatin, and 10 mg/ml soybean trypsin inhibitor, pH 7.5]. In the sequential centrifugation steps applied, the first (600g, 5 min) and second pellets (15,000g, 5 min) were discarded; the third (150,000g, 3 h) pellets were resuspended in the same buffer as a source of membrane enzyme (normalized as to the basis of protein concentration; BCA Protein Assay; Pierce, Rockford, IL). In some experiments, the last supernatant from smooth muscle cells was also used as a cytosolic extract (also normalized as protein content).
Enzymatic assays, based on the chromogenic substrate L-alaninep-nitroanilide (L-Ala-pNA; Sigma-Aldrich; 0.08 -5 mM) and 30 g of membrane or cytosol proteins coincubated at 37°C for 1 to 2 h in 200 l of phosphate-buffered saline, pH 7.4, were performed precisely as previously described (Lendeckel et al., 1996) . Colorless solutions of peptide ligands of the B 1 receptors (agonists or antagonists, 10 M) were used as competitors of L-Ala-pNA hydrolysis in some experiments. Michaelis-Menten enzyme kinetics and competitive inhibition K i values were evaluated using a computer program (Tallarida and Murray, 1987 (Fig. 1B) . Using Lys-des-Arg 9 -BK, the agonist for which the mixture produces the most important change in apparent potency (13.8-fold increase), the effect of the separate components of the peptidase inhibitor mixture was tested (Fig. 1C) . Amastatin is the most important component of the mixture, producing alone a 12.6-fold potency shift, whereas captopril or phosphoramidon effects (1.58-and 1.33-fold increases, respectively) were barely recordable. Puromycin, a selective inhibitor of a cytosolic aminopeptidase (Solhonne et al., 1987; Minnasch et al., 2003) , was ineffective to potentiate Lys-des-Arg 9 -BK (Fig. 1D) . A competition assay for the binding of [ -BK (raw data in Fig. 2 ; K i values for unlabeled peptides in Table 1 derived from the K D value of 0.14 nM for this radioligand and these cells; Sabourin et al., 2002b) . The binding assay was applied to monolayers of smooth muscle cells (minimal impairment of distribution) and in the presence of the same peptidase inhibi- -BK without the peptidase inhibitor mixture did not significantly change the estimated potency (data not shown).
In the contractility assay, a significant gain of potency in the presence of peptidase inhibitors was limited to Lys-desArg 9 -BK and, almost as importantly, to its [D-Phe 8 ] isomer, as shown in Fig. 3 . This representation shows that the contractility EC 50 values moved closer to the binding K i values for the two peptides in the presence of the peptidase inhibitor mixture.
Pharmacological Studies of the Antagonists. The binding competition assay was also applied to several B 1 receptor antagonists ( Fig. 2; K i values in Table 1 ). This evaluation of potency was compared with pA 2 scale values determined using the dextral shift of the contractile concentrationeffect curve for the agonist des-Arg 9 -BK, which itself was not importantly affected by the peptidase inhibitor mixture ( Fig.  4 ; Schild plots from Fig. 4 data in Fig. 5) . The nonpeptide compound A was a very potent and apparently surmountable antagonist, with a pA 2 value of 10.01 Ϯ 0.20 S.E.M. (Fig. 4A) . The historical antagonist prototype [Leu 8 ]des-Arg 9 -BK and the novel peptide antagonist B-10350 were of comparable potencies (pA 2 value of 6.7 and 7.4, respectively; Fig. 4 , C and I). Ac-Lys- [Leu 8 ]des-Arg 9 -BK is a peptide in which the N terminus was protected at the expense of affinity, being less potent than the nonacetylated form (pA 2 7.37 Ϯ 0.08; Fig. 4E , relative to 7.88 Ϯ 0.27 for Lys- [Leu 8 ]des-Arg 9 -BK; Fig. 4G ). It can be seen that the tested antagonists, all surmountable, are dispersed over more than 3 log units on the pA 2 affinity scale. The analysis presented in Fig. 6 shows the relationship between the pA 2 values in the contractility assay and the binding K i value and includes the pA 2 value recently obtained by our laboratory with identical procedures for an additional B 1 receptor antagonist, the nonpeptide compound 11 (Morissette et al., 2004) . In this representation, points corresponding to antagonists that are not aminopeptidase substrates, such as the nonpeptide compounds A and 11 and (Fig. 6) (Figs. 4J and 6 ). The potency of compound A was essentially unaffected by the presence of amastatin (Figs. 4B and 6), consistent with its nonpeptide chemistry. Thus, some peptide antagonists were also subjected to potency estimate distortion because of the presence of aminopeptidase N in the rabbit aorta.
Enzyme Activity. L-Ala-pNA is a usual substrate for aminopeptidase N (Riemann et al., 1999) ; at a standard substrate concentration of 2.5 mM (Lendeckel et al., 1996) , membranes (30 g/reaction) from fresh de-endothelialized rabbit aorta and cultured aortic smooth muscle cells contained measurable aminopeptidase activity (Fig. 7A) . Preincubating aortic rings for 6 h in sterile Krebs' medium, a procedure that sharply up-regulates B 1 receptor expression (Sabourin et al., 2002) , modestly increased the aminopeptidase activity. All these activities were massively inhibited by amastatin (3 M) but much less efficiently by puromycin (5 M). Experiments performed using large lots of cultured smooth muscle cell membranes showed that the enzyme that cleaves L-AlapNA exhibits a K M of 0.63 mM (V max , 4.11 picokatals; Fig.  7B ). Puromycin is a useful inhibitor to differentiate aminopeptidase N (relatively insensitive to it) from an ubiquitous and abundant intracellular puromycin-sensitive form of aminopeptidase (EC 3.4.11.14) that is also inhibited by amastatin but confined to the cytosolic fraction of cells (Solhonne et al., 1987; Minnasch et al., 2003) . This was confirmed in the present experiments by the demonstration of a hydrolytic activity for L-Ala-pNA in the smooth muscle cell cytosol extract (30 g of protein; K M , 0.79 mM, high V max ; Fig. 7B ) that was effectively inhibited by amastatin and puromycin (Fig.  7A) . Therefore, the relative efficacy of inhibitors is consistent with the presence of authentic aminopeptidase N, an ectoenzyme, in smooth muscle cell membranes. Recombinant human APN-GFP expressed in BAECs exhibited a K M of 0.73 mM and was more sensitive to amastatin than to puromycin inhibition (Fig. 7, A and B) , like the smooth muscle cell membrane activity. A significant background aminopeptidase activity was present in the membrane fraction of BAECs (1/3 of that of transfected cells; Fig. 7B ).
The B 1 receptor ligands, added at the fixed concentration of 10 M to the reaction mixtures, were tested for apparent enzyme competition (source of enzyme, membranes of cultured smooth muscle cells). The data were found to approximate competitive inhibition better than noncompetitive kinetics. The hydrolysis of L-Ala-pNA is inhibited by the agonists Lys-des-Arg (Tallarida and Murray, 1987) are reported in text. latter peptides gained 0.9 to 1.0 log unit of potency in the presence of amastatin, whereas Ac-Lys- [Leu 8 ]des-Arg 9 -BK and [Leu 8 ]des-Arg 9 -BK were practically unaffected. These pharmacological data, along with the fitting K i values derived from the L-Ala-pNA hydrolysis competition assay, confirmed a dominant role of aminopeptidase N in the degradation of peptide B 1 receptor antagonists. The effect of acetylation of the N terminus is clear because it affords nearly complete protection against aminopeptidase hydrolysis. B-10350 structure unexpectedly determined the highest apparent affinity for aminopeptidase N (perhaps because the primary reaction product is also a likely substrate of the same enzyme). The free amino terminus and N-terminal Lys residue certainly contribute to affinity for the rabbit B 1 receptor for agonist and antagonist peptides (10- Aminopeptidase N assumes widely divergent functions in the organism such as the digestion of protides at the surface of the intestinal mucosa and the degradation of some cytokines, like interleukin-8, by leukocytes (Riemann et al., 1999) . The peptidase is up-regulated in several tumor cell lines and tumor stromal elements (Riemann et al., 1999; Curnis et al., 2002; Kehlen et al., 2003) . Interestingly, aminopeptidase N is progressively expressed in several organs during the fetal development of the rat, including the aortic wall (Jardinaud et al., 2004) .
The vascular expression of aminopeptidase N, an ectoenzyme bound to membranes and relatively resistant to puromycin, is of interest for the in vivo inactivation of Lys-desArg 9 -BK, the likely physiological agonist for this receptor in the human, rabbit, and pig (Leeb-Lundberg et al., 2005) . A very recent study of an alternate model, the human umbilical artery, has led to substantially similar conclusions, although limited to the B 1 receptor agonists and based only on the pharmacological analysis of contractility (Pelorosso et al., 2005) . In the present study, the comparative determination of absolute receptor affinity using a radioligand competition assay and of the capacity of each peptide to compete for the hydrolysis of a synthetic aminopeptidase N substrate allowed us to show that the observed contractile potency of the B 1 receptor agonists in the isolated rabbit aorta is a function of both parameters. Furthermore, the present study shows unequivocally that susceptibility to aminopeptidase N is critical for the design of hydrosoluble peptide antagonists, as illus- jpet.aspetjournals.org trated with B-10350. Hydrosoluble antagonists may be well adapted to i.v. administration in intensive care units for future applications that are still under investigation, such as sepsis, wasting states, and pain (Leeb-Lundberg et al., 2005) . Alternatively, peptide antagonists may be suitable for topical administration with minimal systemic distribution. For example, allergic inflammation of the human nasal mucosa determines a local B 1 receptor up-regulation (Christiansen et al., 2002) , and the possible benefits of receptor blockade remain to be determined in this condition.
